Stocks

Magazine articles on individual stocks, valuation, accounting standards, IPO's, brokerages, exchanges.

Old Articles: <Older 25441-25450 Newer>

The Motley Fool August 14, 2007 Rick Aristotle Munarriz	Jamba Liar The smoothie giant is on a rocky road. It seems as if every few weeks Jamba is creeping lower into the single digits. If the trend continues, you'll be able to exchange a single share certificate for a 16-ounce smoothie.
The Motley Fool August 14, 2007 Anders Bylund	AMD: No Barcelona Bargains With any luck -- and a steady trickle of insider leaks -- investors might be able to form a decent image of how this round in the Intel-AMD wars will play out, before it actually happens.
The Motley Fool August 14, 2007 Lawrence Rothman	Nordstrom Knows Quality Luxury retailer Nordstrom serves up an attractive price. July comps show an impressive jump up, share prices have dropped down; is this an opportunity to pick up some stock on sale?
The Motley Fool August 14, 2007 Rich Smith	Foolish Forecast: Salesforce.com Rings In The on-demand software pioneer will once again skip ahead of the pack shortly and release its fiscal second-quarter 2008 earnings results. Investors, here is what you can expect to see.
The Motley Fool August 14, 2007 Timothy M. Otte	Is Sears Faltering? The retailer reports lower second-quarter comps. Investors, take note.
The Motley Fool August 14, 2007 Billy Fisher	A Surging Small Cap in Canada Drugmaker Axcan reports a record third-quarter. Investors, this stock has soared more than 42% over the past 52 weeks.
The Motley Fool August 14, 2007 Lawrence Rothman	Timeless Style at TJX For investors, this retail company is serving up all the perennial favorites.
The Motley Fool August 14, 2007 Todd Wenning	Get 'Em While They're Cheap The recent market volatility has caused many foreign exchanges to fare even worse than the domestic ones in recent weeks, creating buying opportunities abroad. Here are some possibilities.
The Motley Fool August 14, 2007 Brian Orelli	Drugmaker Growth Without the FDA Do you have one of those stomachs that just can't take the ups and downs of clinical trial data and FDA approval decisions? Buy stocks in the companies that support the drug makers.
The Motley Fool August 14, 2007 Rick Aristotle Munarriz	Orbitz Comes Full Circle Orbitz improves in its first quarter as a public company. Getting in for less than last month's initial investors is compelling. However, until Orbitz begins growing as quickly as its peers on a consistent basis, markdowns will be warranted.
<Older 25441-25450 Newer> Return to current articles.